Clear All
796 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
J9145 Daratumumab Darzalex 10 mg Immunotherapy Monoclonal Antibody CD38 No 2015 Jan 1, 2017 In Use
J9049 Bortezomib (Hospira) Bortezomib (Hospira) 0.1mg Chemotherapy Proteasome Inhibitor 26S No 2022 Dec 21, 2022 In Use
J9276 Zanidatamab-hrii ZIIHERA 2mg Immunotherapy Monoclonal Antibody HER2 No 2024 Jul 9, 2025 In Use
J9096 Cyclophosphamide Cyclophosphamide lyophilized 1 g Chemotherapy Alkylating Agent Nitrogen Mustard No 1959 Jan 1, 1994 Dec 31, 2010 No Longer Used
J9174 Docetaxel (beizray) Beizray 1mg Chemotherapy Antimitotic Agent Taxane No 2024 Jul 9, 2025 In Use
J9324 Pemetrexed disodium Pemrydi-rtu 10mg Chemotherapy Antimetabolite Folic Acid Analog No 2023 Dec 7, 2023 In Use
J9323 Pemetrexed ditromethamine Pemetrexed ditromethamine 10mg Chemotherapy Antimetabolite Folic Acid Analog No 2022 Jul 11, 2023 In Use
S9338 Immunotherapy - non specific Home infusion therapy, immunotherapy NA Immunotherapy No Jan 1, 2002 In Use
J9400 Ziv-aflibercept Zaltrap 1 mg Chemotherapy Recombinant Fusion Protein VEGF-IgG1 No 2012 Jan 1, 2014 In Use
J9027 Clofarabine Clolar 1 mg Chemotherapy Antimetabolite Purine Analog No 2004 Jan 1, 2006 In Use
C9080 Melphalan flufenamide Pepaxto 1mg Chemotherapy Alkylating Agent Nitrogen Mustard No 2021 Jul 23, 2021 Sep 27, 2021 No Longer Used
J1326 Zolbetuximab-clzb Vyloy 2mg Immunotherapy Monoclonal Antibody CLDN18.2 No 2024 Jul 9, 2025 In Use
Q5171 Denosumab (boncres) Boncresa 1mg Ancillary Therapy Monoclonal Antibody RANKL No 2025 Jun 17, 2026 In Use
J2860 Siltuximab Sylvant 10 mg Immunotherapy Monoclonal Antibody IL-6 No 2014 Jan 1, 2016 In Use
J1260 Dolasetron Mesylate Anzemet 10 mg Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist No 1997 Jan 1, 2000 In Use
C9082 Dostarlimab-gxly Jemperli 100mg Immunotherapy Checkpoint Inhibitor PD-1 No 2021 Sep 27, 2021 Jan 26, 2022 No Longer Used
C9492 Durvalumab Imfinzi 10 mg Immunotherapy Checkpoint Inhibitor PD-L1 No 2017 Oct 1, 2017 In Use
J9173 Durvalumab Imfinzi 10mg Immunotherapy Checkpoint Inhibitor PD-L1 No 2017 Jan 1, 2019 In Use
Q2048 Doxorubicin Doxil 10 mg Chemotherapy Antitumor Antibiotic Anthracycline No 1995 Jul 1, 2012 Dec 31, 2013 No Longer Used
Q5158 Denosumab-bnht Bomyntra, Conexxence 1mg Immunotherapy Monoclonal Antibody RANKL No 2025 Sep 8, 2025 In Use
J9000 Doxorubicin Adriamycin 10 mg Chemotherapy Antitumor Antibiotic Anthracycline No 1989 Jan 1, 1984 In Use
J9160 Denileukin Diftitox Ontak 300 mcg Immunotherapy Cytokine Interleukin-2 No 1999 Jan 1, 2001 In Use
J9019 Asparaginase Erwinaze 10, 000 units (I.U.) Chemotherapy Miscellaneous Agent Enzyme No 2011 Jan 1, 2013 Jan 12, 2026 In Use
J1434 Fosaprepitant Focinvez 1mg Ancillary Therapy Antiemetic Substance P/Neurokinin 1 No 2023 Apr 17, 2024 In Use
J9319 Romidepsin, lyophilized Istodax 0.1mg Chemotherapy Enzyme Inhibitor HDAC No 2010 Sep 27, 2021 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.